MicroRNAs in urine are not biomarkers of multiple myeloma.
Sedlaříková L et al. J Negat Results Biomed. 2015 Sep 23;14(1):16.

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L et al. PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294.

Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma – A Retrospective Study.
Huang SY et al. PLoS One. 2015 Sep 17;10(9):e0137552. doi: 10.1371/journal.pone.0137552. eCollection 2015.

Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
Zhou M et al. J Exp Clin Cancer Res. 2015 Sep 11;34(1):102. doi: 10.1186/s13046-015-0219-5.

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
Kim C et al. Korean J Intern Med. 2015 Sep;30(5):675-83. doi: 10.3904/kjim.2015.30.5.675. Epub 2015 Aug 28.

State-of-the-art of bone marrow imaging in multiple myeloma.
Martí-Bonmatí L et al. Curr Opin Oncol. 2015 Sep 8. [Epub ahead of print].

Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Kuiper R et al. Blood. 2015 Sep 1. pii: blood-2015-05-644039. [Epub ahead of print].